SCHEMBL27140255

SCHEMBL27140255

CN(CCCC1CCN(C(=O)OCc2ccccc2)CC1)C(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
FAAH O00519 1/20 0.52
CYP2C19 P33261 1/20 0.50
GRIN2B Q13224 11/20 0.48
HTT P42858 1/20 0.48
CYP2D6 P10635 4/20 0.48
CYP2C9 P11712 4/20 0.48
GPR119 Q8TDV5 1/20 0.47
CYP3A4 P08684 3/20 0.46
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
YAP1 P46937 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6651386 0.94 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9AFAAHCYP2C19
SCHEMBL21996926 0.87 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9AFAAHCYP2C19
SCHEMBL21069500 0.87 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9AFAAHCYP2C19
SCHEMBL27141260 0.86 JAK2 (0.51) SMN1; SMN2NPC1RAB9AFAAHCYP2C19
SCHEMBL21997461 0.85 KDM4E (0.52) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL22123715 0.85 HTT (0.61) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL30802046 0.84 SIGMAR1 (0.48) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL30802045 0.84 SIGMAR1 (0.48) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL7366193 0.84 FAAH (0.47) SMN1; SMN2NPC1RAB9AFAAHCYP2C19
SCHEMBL22123738 0.82 HTT (0.63) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 US disclosed
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 US disclosed
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 EP disclosed
WO-2022223033-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海领泰生物医药科技有限公司 2022-10-27 WO disclosed
WO-2022223039-A1 SOS1 DEGRADER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海领泰生物医药科技有限公司 2022-10-27 WO disclosed
WO-2022223034-A1 SOS1 DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海领泰生物医药科技有限公司 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SOS1, RAC1, RSU1 SMN1; SMN2 1503/4885NPC1 1660/4885RAB9A 218/4885
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF RAC1, SOS1, RSU1 SMN1; SMN2 1681/4885NPC1 1731/4885RAB9A 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.